The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06463587




Registration number
Help: Registration number
NCT06463587
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
11/06/2024
Date registered
Help: Date registered
18/06/2024
Date last updated
Help: Date last updated
21/10/2026

Titles & IDs
Public title
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Additional trial identifiers [1] 0 0
2023-507746-83-00
Additional trial identifiers [2] 0 0
MS700568_0183
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Generalized Myasthenia Gravis 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Neurological 0 0 0 0
Other neurological disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Other interventions - Placebo
Treatment: Drugs - Cladribine Low Dose
Treatment: Drugs - Cladribine High Dose

Placebo comparator: Placebo - DBPC Period: Participants will be administered with Placebo, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5.

BE Period: Participants initially randomized to placebo matched to cladribine in DBPC period will receive cladribine Low Dose or High Dose, orally as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated if clinically justified with placebo matched to cladribine.

RT Period: If clinically justified, participants requiring retreatment with cladribine Low Dose or High Dose or cladribine supplemental dose will receive the selected dose of cladribine or matching placebo regimen.

Experimental: Cladribine Low Dose - DBPC Period: Participants will be administered with cladribine Low Dose, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5.

BE Period: Participants initially randomized to cladribine Low Dose in DBPC period will receive placebo matched to cladribine as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated with cladribine supplemental dose if clinically justified.

RT Period: If clinically justified, participants requiring retreatment with cladribine Low Dose regimen and/or supplemental dose will receive the selected dose of cladribine or matching placebo regimen.

Experimental: Cladribine High Dose - DBPC Period: Participants will be administered cladribine High Dose, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5.

BE Period: Participants initially randomized to cladribine High Dose in DBPC period will receive placebo matched to cladribine as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated with cladribine supplemental dose if clinically justified.

RT Period: If clinically justified, participants requiring retreatment with cladribine High Dose regimen and/or supplemental dose will receive the selected dose of cladribine or matching placebo regimen.


Other interventions: Placebo
Participants will receive placebo matched to cladribine in two courses separated by 4 weeks.

Treatment: Drugs: Cladribine Low Dose
Participants will receive cladribine low dose in two courses separated by 4 weeks.

Treatment: Drugs: Cladribine High Dose
Participants will receive cladribine high dose in two courses separated by 4 weeks.

Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Change from Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Scale Score at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Timepoint [1] 0 0
Baseline, Week 24
Secondary outcome [1] 0 0
Change from Baseline in Quantitative Myasthenia Gravis (QMG) Scale Score at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Timepoint [1] 0 0
Baseline, Week 24
Secondary outcome [2] 0 0
Percentage of MG-ADL Responders at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Timepoint [2] 0 0
At Week 24
Secondary outcome [3] 0 0
Change from Baseline in Myasthenia Gravis Composite (MGC) Scale Score at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Timepoint [3] 0 0
Baseline, Week 24
Secondary outcome [4] 0 0
Percentage of Quantitative Myasthenia Gravis (QMG) Scale Responders at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Timepoint [4] 0 0
At Week 24
Secondary outcome [5] 0 0
Time From Initial Cladribine Full Dose Treatment to First Retreatment or Rescue Treatment up to end of Study
Timepoint [5] 0 0
Up to End of Study (Week 144)
Secondary outcome [6] 0 0
Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)
Timepoint [6] 0 0
Up to End of Study (Week 144)
Secondary outcome [7] 0 0
Number of participants with Adverse Events (AEs) by Severity as per National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0
Timepoint [7] 0 0
Up to End of Study (Week 144)
Secondary outcome [8] 0 0
Number of Participants with Abnormal Laboratory Variables including Absolute Lymphocyte Count and Vital Signs
Timepoint [8] 0 0
Up to End of Study (Week 144)
Secondary outcome [9] 0 0
Pharmacokinetic (PK) Plasma Concentration of Cladribine
Timepoint [9] 0 0
Pre-dose, 0.25, 1, 2, 3, 4, 6, 8 and 24 hours post-dose
Secondary outcome [10] 0 0
Change from Baseline in the Revised Myasthenia Gravis Quality of Life - 15 Scale (MG-Qol15r) Score at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Timepoint [10] 0 0
Baseline, Week 24
Secondary outcome [11] 0 0
Number of Participants with Abnormal ECG parameters
Timepoint [11] 0 0
Up to End of Study (Week 144)

Eligibility
Key inclusion criteria
* Adults of = 18 years of age at the time of signing the informed consent.
* Diagnosis of Myasthenia Gravis with generalized muscle weakness, meeting clinical criteria for Myasthenia Gravis Foundation of America Class II to IVa classification.

* In participants positive for Acetylcholine receptor antibody (anti-AChR) or muscle-specific kinase antibody(anti-MuSK)
* In participants that are autoantibody seronegative i.e. not positive for anti-AChR and anti-MuSK antibodies and participants who are positive for anti-low-density lipoprotein receptor-related protein 4 antibodies (anti-LRP4)
* Has a Screening and Baseline MG-ADL score more than or equal to (>=) 6 with >= 50 percentage (%) of the total score due to non-ocular symptoms. Screening and Baseline MG-ADL scores must be stable. The difference between the Screening and Baseline scores should not be more than 2 and there should be no reported MG exacerbation during the Screening period
* If treated with oral corticosteroids: should be on a stable daily dose for at least 3 months prior to and during screening. In such case, the daily dose of oral steroids should not exceed 20 milligrams(mg)/day for prednisone/ prednisolone, 16 mg/day for methylprednisolone, 3 mg/day for dexamethasone, or 80 mg for hydrocortisone or equivalent doses for other corticosteroids.
* If treated with acetylcholinesterase inhibitor should be on a stable daily dose (pyridostigmine dose = 480 mg/day or neostigmine = 300 mg/day) for at least 3 months prior to and during screening
* Have a body weight >= 40 kilograms
* Other protocol defined inclusion criteria could apply
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
* Immunologic disorder other than MG or any other condition requiring chronic oral, intravenous, intramuscular, or intraarticular corticosteroid therapy. Well-controlled thyroid disease, as per the Treating Investigator or the participants regular treating physician recorded in the source documents, is not exclusionary
* Molecularly characterized or suspected congenital myasthenic syndrome, Lambert-Eaton myasthenic syndrome, inherited myopathy, muscular dystrophy, acquired myopathy or any other neurologic or systematic disease that mimics MG muscular weakness
* Active, clinically significant viral, bacterial, or fungal infection, including brain MRI or chest X-ray findings consistent with signs of infection such as PML or TB, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 8 weeks prior or during Screening, or completion of oral anti-infectives within 8 weeks prior or during Screening. Vaginal candidiasis, onychomycosis, and genital or oral herpes simplex virus considered by the Investigator to be sufficiently controlled would not be exclusionary
* Has a history of or current diagnosis of active tuberculosis (TB) or is currently undergoing treatment for latent TB infection or has an untreated latent TB infection as determined by documented results within 3 months of the Screening Visit of a positive TB skin test .
* Active malignancy, or history of cancer or signs of malignancy in any Screening assessment
* Treatment with nonsteroidal immunosuppressants, used in gMG, such as azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, cyclophosphamide, tacrolimus within 4 weeks prior to randomization
* Treatment with FcRn or complement inhibitors (such as eculizumab, rozanolixizumab efgartigimod, ravulizumab, zilucoplan or nipocalimab) within 8 weeks prior to randomization
* History of thymectomy within 6 months prior to Screening.
* History of generalized seizures (except for history of febrile seizures during the participant's childhood).
* Negative or indeterminate for Varicella Zoster Virus antibodies at screening
* History of myasthenic crisis in the last 12 months prior to and during screening
* History of recurrent infections (that is 3 or more infections per year documented in available source data) within the last 2 years
* Discontinuation of treatment with any non-steroidal immunosuppressants used in gMG, such as azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, cyclophosphamide, tacrolimus within the last 6 months prior to Screening
* If treated with non-steroidal immunosuppressants for gMG, the dose at Screening higher than 50 mg/day for azathioprine, 500 mg/day for mycophenolate mofetil, 1 mg/day for tacrolimus, 50 mg/day for cyclosporine, 25 mg/day for cyclophosphamide, or 7.5 mg/week for methotrexate
* Participation in clinical study of any investigational drug within 6 months, or 5 half-lives of the investigational drug used in the previous clinical study prior to randomization, whichever is longer. However, participants with any prior exposure to cladribine may not enter the study regardless of timing of exposure
* Other protocol defined exclusion criteria could apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Brain and Mind Research Institute - Camperdown
Recruitment hospital [2] 0 0
Sunshine Coast University Hospital - Birtinya
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - PARENT - South Brisbane
Recruitment hospital [4] 0 0
John Hunter Hospital - PARENT - City of Burnside
Recruitment hospital [5] 0 0
Box Hill Hospital - PARENT - Box Hill
Recruitment hospital [6] 0 0
Gold Coast University Hospital - PARENT - Southport
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
4575 - Birtinya
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
SA 5072 - City of Burnside
Recruitment postcode(s) [5] 0 0
3128 - Box Hill
Recruitment postcode(s) [6] 0 0
- Southport
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
South Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Vermont
Country [13] 0 0
United States of America
State/province [13] 0 0
Virginia
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
Argentina
State/province [15] 0 0
Ciudad Autonoma Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Córdoba
Country [17] 0 0
Argentina
State/province [17] 0 0
Rosario
Country [18] 0 0
Argentina
State/province [18] 0 0
San Juan
Country [19] 0 0
Argentina
State/province [19] 0 0
San Miguel de Tucumán
Country [20] 0 0
Belgium
State/province [20] 0 0
Leuven
Country [21] 0 0
Belgium
State/province [21] 0 0
Liège
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Montana
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Pleven
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Plovdiv
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Sofia
Country [26] 0 0
Canada
State/province [26] 0 0
British Columbia
Country [27] 0 0
China
State/province [27] 0 0
Anhui
Country [28] 0 0
China
State/province [28] 0 0
Beijing Municipality
Country [29] 0 0
China
State/province [29] 0 0
Guangdong
Country [30] 0 0
China
State/province [30] 0 0
Guizhou
Country [31] 0 0
China
State/province [31] 0 0
Hebei
Country [32] 0 0
China
State/province [32] 0 0
Henan
Country [33] 0 0
China
State/province [33] 0 0
Hu'nan
Country [34] 0 0
China
State/province [34] 0 0
Hubei
Country [35] 0 0
China
State/province [35] 0 0
Jilin
Country [36] 0 0
China
State/province [36] 0 0
Liaoning
Country [37] 0 0
China
State/province [37] 0 0
Shanghai Municipality
Country [38] 0 0
China
State/province [38] 0 0
Shanxi
Country [39] 0 0
China
State/province [39] 0 0
Sichuan
Country [40] 0 0
France
State/province [40] 0 0
Alpes Maritimes
Country [41] 0 0
France
State/province [41] 0 0
Bas Rhin
Country [42] 0 0
France
State/province [42] 0 0
Isere
Country [43] 0 0
France
State/province [43] 0 0
Paris
Country [44] 0 0
France
State/province [44] 0 0
Puy De Dome
Country [45] 0 0
France
State/province [45] 0 0
Rhone
Country [46] 0 0
France
State/province [46] 0 0
Val De Marne
Country [47] 0 0
Georgia
State/province [47] 0 0
Tbilisi
Country [48] 0 0
Germany
State/province [48] 0 0
Baden-Wurttemberg
Country [49] 0 0
Germany
State/province [49] 0 0
Lower Saxony
Country [50] 0 0
Germany
State/province [50] 0 0
North Rhine-Westphalia
Country [51] 0 0
Germany
State/province [51] 0 0
Saxony
Country [52] 0 0
Germany
State/province [52] 0 0
Schleswig-Holstein
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Greece
State/province [54] 0 0
Larissa
Country [55] 0 0
Greece
State/province [55] 0 0
Pátrai
Country [56] 0 0
Greece
State/province [56] 0 0
Thessaloniki
Country [57] 0 0
Hungary
State/province [57] 0 0
Szeged
Country [58] 0 0
India
State/province [58] 0 0
Andhra Pradesh
Country [59] 0 0
India
State/province [59] 0 0
Karnataka
Country [60] 0 0
India
State/province [60] 0 0
Maharashtra
Country [61] 0 0
Italy
State/province [61] 0 0
Bergamo
Country [62] 0 0
Italy
State/province [62] 0 0
Bologna
Country [63] 0 0
Italy
State/province [63] 0 0
Genova
Country [64] 0 0
Italy
State/province [64] 0 0
Milan
Country [65] 0 0
Italy
State/province [65] 0 0
Pavia
Country [66] 0 0
Italy
State/province [66] 0 0
Rome
Country [67] 0 0
Italy
State/province [67] 0 0
Treviso
Country [68] 0 0
Japan
State/province [68] 0 0
Chiba
Country [69] 0 0
Japan
State/province [69] 0 0
Fukuoka
Country [70] 0 0
Japan
State/province [70] 0 0
Fukushima
Country [71] 0 0
Japan
State/province [71] 0 0
Hokkaido
Country [72] 0 0
Japan
State/province [72] 0 0
Iwate
Country [73] 0 0
Japan
State/province [73] 0 0
Kagawa-ken
Country [74] 0 0
Japan
State/province [74] 0 0
Nagasaki
Country [75] 0 0
Japan
State/province [75] 0 0
Saitama
Country [76] 0 0
Japan
State/province [76] 0 0
Tokyo-To
Country [77] 0 0
Japan
State/province [77] 0 0
Suita-shi
Country [78] 0 0
Poland
State/province [78] 0 0
Gdansk
Country [79] 0 0
Poland
State/province [79] 0 0
Krakow
Country [80] 0 0
Poland
State/province [80] 0 0
Warsaw
Country [81] 0 0
Poland
State/province [81] 0 0
Zabrze
Country [82] 0 0
Romania
State/province [82] 0 0
Bucharest
Country [83] 0 0
Romania
State/province [83] 0 0
Constan?a
Country [84] 0 0
Romania
State/province [84] 0 0
Târgu Mures
Country [85] 0 0
Serbia
State/province [85] 0 0
Belgrade
Country [86] 0 0
Serbia
State/province [86] 0 0
Kragujevac
Country [87] 0 0
Serbia
State/province [87] 0 0
Niš
Country [88] 0 0
Serbia
State/province [88] 0 0
Novi Sad
Country [89] 0 0
South Korea
State/province [89] 0 0
Daegu
Country [90] 0 0
South Korea
State/province [90] 0 0
Gwangju
Country [91] 0 0
South Korea
State/province [91] 0 0
Seoul
Country [92] 0 0
Spain
State/province [92] 0 0
Barcelona
Country [93] 0 0
Spain
State/province [93] 0 0
Córdoba
Country [94] 0 0
Spain
State/province [94] 0 0
Principality of Asturias
Country [95] 0 0
Spain
State/province [95] 0 0
Valencia
Country [96] 0 0
Sweden
State/province [96] 0 0
Göteborg
Country [97] 0 0
Sweden
State/province [97] 0 0
Karlstad
Country [98] 0 0
Sweden
State/province [98] 0 0
Stockholm
Country [99] 0 0
Switzerland
State/province [99] 0 0
Bern
Country [100] 0 0
Taiwan
State/province [100] 0 0
Kaohsiung City
Country [101] 0 0
Taiwan
State/province [101] 0 0
Taichung
Country [102] 0 0
Taiwan
State/province [102] 0 0
Taipei
Country [103] 0 0
Turkey (Türkiye)
State/province [103] 0 0
Ankara
Country [104] 0 0
Turkey (Türkiye)
State/province [104] 0 0
Atakum/SAMSUN
Country [105] 0 0
Turkey (Türkiye)
State/province [105] 0 0
Istanbul
Country [106] 0 0
Turkey (Türkiye)
State/province [106] 0 0
Izmir
Country [107] 0 0
Turkey (Türkiye)
State/province [107] 0 0
Kocaeli
Country [108] 0 0
Turkey (Türkiye)
State/province [108] 0 0
Mersin
Country [109] 0 0
Turkey (Türkiye)
State/province [109] 0 0
Trabzon
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Greater London
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Nottinghamshire
Country [112] 0 0
United Kingdom
State/province [112] 0 0
South Yorkshire

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Address
Country
Secondary sponsor
Nil
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
EMD Serono Research & Development Institute, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Responsible
Address 0 0
EMD Serono Research & Development Institute, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
US Medical Information
Address 0 0
Country 0 0
Phone 0 0
888-275-7376
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
IPD supporting publicly available results will be evaluated for sharing.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR), Analytic code
When will data be available (start and end dates)?
IPD from completed trials will be publicly available within 6 months after all of the following events:

* Approval of a product/new indication by major authorities (FDA, EMA, PMDA if requested) with no pending submissions
* Public results via primary manuscript or trial registry disclosure
* Legal authority to share data
* Privacy protections are in place

If approval is not sought or development is globally discontinued, data will be publicly available within 18 months after global trial completion. Further information on how to request data can be found on our website bit.ly/IPD21
Available to whom?
Qualified researchers may propose access to IPD from sponsored trials via https://vivli.org/members/ourmembers/.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://vivli.org/


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.